Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CORVax12
- Development stage
- Unknown
- Lead developer
- OncoSec Medical
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intradermal
01
Overview
**CORVax12** is a prophylactic DNA plasmid vaccine candidate developed by OncoSec Medical Incorporated in collaboration with Providence Cancer Institute and researchers from the NIH's National Institute of Allergy and Infectious Diseases. It encodes the SARS-CoV-2 spike (S) glycoprotein, a highly conserved consensus sequence based on early viral isolates, delivered via electroporation using the IGEA CLINIPORATOR® device into the dermis to enhance uptake and immunogenicity. Combined with pIL-12 (tavokinogene telseplasmid), it aims to drive a coordinated Th1-biased immune response, including neutralizing antibodies, CD8+ and CD4+ T cells, and NK/macrophage activation, leveraging the skin's antigen-presenting cells for robust cellular and humoral anti-viral protection against COVID-19.[1][7][13]
- Other names
- SARS-CoV-2 spike (S) protein plasmid DNA vaccine
02
Targets
IL-12R (Interleukin-12 receptor)MHC II (Major histocompatibility complex class II receptor)γδ TCR (T-cell receptor)SARS-CoV-2 spike
Beyond the preview
Go deeper on CORVax12.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CORVax12.